Application of melanoma-derived exosome in medicine for treating psoriasis

By targeting the IL-17a signaling pathway with melanoma-derived exosomes and utilizing the transcytosis mechanism mediated by miRNA molecules and RhoA protein, an effective treatment for psoriasis has been achieved, overcoming the safety and permeability limitations of existing treatments and providing a new therapeutic approach.

CN119015300APending Publication Date: 2024-11-26CENT SOUTH UNIV
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202411414101.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-10-11
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

Existing treatments for psoriasis suffer from shortcomings in safety, cost, and effectiveness. In particular, topical administration has low skin penetration efficiency, and traditional drugs may cause toxic side effects.

Method used

Using exosomes derived from melanoma, especially those containing mmu-miR-320-3p and mmu-miR-126-5p, the treatment targets the IL-17a signaling pathway, inhibits T cell activation and Th17 cell differentiation, and achieves percutaneous penetration through RhoA protein-mediated intercellular transcytosis, directly applied to the lesion skin for treatment.

Benefits of technology

It achieved effective relief of psoriasis, rebalanced abnormally active T-cell signaling pathways, reduced skin inflammation, provided a new treatment approach, improved transdermal drug permeability, and reduced toxic side effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119015300A_ABST
    Figure CN119015300A_ABST
Patent Text Reader

Abstract

The invention provides an application of a melanoma-derived exosome in a drug for treating psoriasis, and belongs to the technical field of biological medicine.According to the scheme, immunosuppressor functional molecules in a tumor microenvironment are introduced, so that abnormally active T cells in psoriasis and signal channels of the T cells can be rebalanced, and the psoriasis treatment effect is improved. B16-Exo has excellent percutaneous penetration activity, is derived from RhoA protein in a membrane structure of B16-Exo, can mediate transcellular transendocytosis of exosomes in epidermal cells, provides a new strategy for percutaneous penetration promotion of drugs, and provides a new therapeutic approach for psoriasis and other autoimmune diseases through RNA sequencing and bioinformatics analysis, so that the application of B16-Exo in the treatment of psoriasis and other autoimmune diseases is developed, and the application of B16-Exo in the treatment of psoriasis and other autoimmune diseases in the treatment of psoriasis and other autoimmune diseases in the treatment of psoriasis and other autoimmune diseases is developed. According to the application, mmu-miR-320-3p is excavated as a key immunomodulatory molecule, and the activity of T cells and the expression of inflammatory factors can be regulated by inhibiting an IL-17 signal channel mediated by Th17 cells, so that pathological inflammation of psoriasis is relieved, and local immune response of skin is relieved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedicine technology, and specifically relates to the application of melanoma-derived exosomes in drugs for treating psoriasis. Background Art

[0002] Psoriasis is a chronic inflammatory skin disease. Currently, there is a lack of safe, economical, and effective treatments. It manifests as epidermal hyperplasia and red, thick, scaly plaques, which are the result of excessive proliferation and abnormal differentiation of keratinocytes and massive infiltration of inflammatory immune cells. These cells interfere with each other through proinflammatory mediators, ultimately contributing to the vicious cycle of psoriasis. Conventional treatment of psoriasis involves systemic administration of immunosuppressants (such as methotrexate) that may cause liver and kidney toxicity, or topical application of corticosteroids (such as betamethasone) and vitamin D analogs (such as calcipotriol) that may cause skin irritation and atrophy. In recent years, anti-psoriatic biologics represented by monoclonal antibodies have developed rapidly, mainly by blocking key inflammatory pathways (such as anti-interleukin 17). However, these drugs require systemic injection, are costly to treat, and have the risk of infection. In comparison, topical administration has fewer toxic side effects, but the stratum corneum (SC) of the skin forms an absorption barrier, which greatly reduces the skin penetration efficiency of the drug.

[0003] Therefore, there is an urgent need to develop an economical, effective and less side-effect-prone treatment strategy for psoriasis. Summary of the invention

[0004] In order to solve the above technical problems, the present invention provides an application of melanoma-derived exosomes in drugs for the treatment of psoriasis. The two core functional miRNA molecules in the exosomes, mmu-miR-320-3p and mmu-miR-126-5p, can target the IL-17a signaling pathway, thereby inhibiting the activation and proliferation of T cells and the differentiation of Th17 cells, thereby achieving the relief of psoriasis.

[0005] To achieve the above objectives, the present invention first provides an application of melanoma-derived exosomes in a drug for treating psoriasis, wherein the drug comprises melanoma-derived exosomes and a matrix.

[0006] Preferably, the method for preparing melanoma-derived exosomes is as follows: B16-F10 cells and their supernatant are separated from the culture system, the supernatant is centrifuged to remove cells, debris and large vesicles, and then filtered through a filter to exclude apoptotic bodies and microvesicles, the filtrate is ultracentrifuged to obtain a precipitate, resuspended, and ultracentrifuged again to finally obtain a precipitate as exosomes.

[0007] Preferably, the centrifugal force for removing cells and debris is 2,000 g, and the centrifugation time is 10 minutes. The centrifugal force for removing large vesicles is 10,000 g, and the centrifugation time is 10 to 60 minutes.

[0008] Preferably, the pore size of the filter is 0.22 μm.

[0009] Preferably, the centrifugal force of the filtrate ultracentrifugation is 100,000 g and the ultracentrifugation time is 90 min.

[0010] Preferably, the effective pharmacological concentration of the melanoma-derived exosomes in the drug is 0.01 mg / mL, and the matrix comprises carbomer gel.

[0011] Preferably, the drug is applied externally by directly applying it to the affected skin.

[0012] The mechanism of treatment of this regimen is as follows:

[0013] Topical application of melanoma homogenate tissue can alleviate the symptoms of the mouse psoriasis model. This protocol has confirmed that it mainly exerts its therapeutic effect through melanoma exosomes in the tissue. On the one hand, melanoma exosomes can target and recognize T cells, and act on the IL-17a signaling pathway through the miRNA in its structure, thereby inhibiting the inflammatory response and cell proliferation of T cells; on the other hand, exosomes achieve transdermal penetration through intercellular transcytosis mediated by the RhoA protein on their surface, mediate their entry into immune cells, and exert a therapeutic effect.

[0014] Compared with the prior art, the present invention has the following beneficial effects:

[0015] (1) This approach can rebalance the abnormally active T cells and their signaling pathways in psoriasis by introducing immunosuppressant functional molecules into the tumor microenvironment. This approach is different from traditional treatment models and can open up new treatment pathways for psoriasis and other autoimmune diseases.

[0016] (2) Psoriasis and malignant tumors have diametrically opposite pathological changes. This approach creatively utilizes the immunosuppressive regulation in the tumor microenvironment to alleviate abnormal immune activation in psoriasis, thereby achieving the treatment of psoriasis.

[0017] (3) B16-Exo has excellent transdermal penetration activity, which is derived from the RhoA protein in its membrane structure, which can mediate the transcytosis of exosomes in epidermal cells. The transcytosis characteristics of exosomes and the way they change the fluidity of cell membranes also provide new strategies for enhancing the transdermal penetration of drugs. BRIEF DESCRIPTION OF THE DRAWINGS

[0018] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0019] Figure 1 This is an evaluation of the therapeutic effect of melanoma tissue homogenate on psoriasis model mice in Experimental Example 1. A is a melanoma tissue homogenate treatment regimen under the prevention model. B is an image of skin lesions on the back of mice after treatment with tumor tissue homogenate of different concentrations. C is a curve of the PASI score change of mice after treatment with tumor tissue homogenate of different concentrations. D is a microscopic structure of mouse skin sections after different treatments shown by H&E staining, and the arrow in the figure indicates the thickness of the epidermis.

[0020] Figure 1 This is the evaluation of the therapeutic effect of melanoma tissue homogenate on psoriasis model mice in Experimental Example 2. E is a schematic diagram of the separation process of melanoma B16-F10 cells, supernatant and exosomes; F is a particle size distribution diagram and transmission electron microscopy image of B16-F10 cell exosomes; G is Western blot verification of the expression of marker proteins CD63 and Alix in B16-Exo cells and their exosomes; H is the appearance of skin lesions of mice after different treatments, from left to right: control group, B16-F10 cell treatment group, supernatant treatment group and B16-F10 cell exosome treatment group; I is the change trend of PASI scores in different treatment groups during treatment; J is a tissue section showing the skin of mice in the Control and different treatment groups through H&E staining;

[0021] Figure 2This is the evaluation of the therapeutic effect of melanoma exosomes on psoriasis model mice in Experimental Example 3. A is a representative picture of the skin of mice in different treatment groups, from left to right: control group, IMQ group, Blank gel, B16-Exo gel group, the picture shows the skin condition after treatment; B is the daily PASI score change curve of each treatment group during the seven-day treatment period; C is the HE staining section of the mouse skin tissue of each group, scale = 100μm; D is the in vitro picture of the mouse spleen after treatment in different groups; E is the relative spleen weight of mice in different treatment groups (Mean±SD, n=5); F is the HE staining section of the spleen tissue of mice in each group, scale = 100μm; the arrow indicates the change in the volume of lymphoid follicles; GK is the relative level of key inflammatory factors in the skin tissue of mice in each treatment group (Mean±SD, n=5), including IL-23 (G), IL-17 (H), TNF-α (I), IL-1β (J) and IL-6 (K), * indicates statistically significant difference (*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001);

[0022] Figure 3 The results of transcriptome sequencing analysis of skin tissue samples treated with IMQ, Blank gel, and B16-Exo gel in Experimental Example 4. A is a heat map showing the differences in chemokine activity, epidermal development, and keratin gene expression levels between the Control group (samples A1, A2, A3), the IMQ-treated group (samples B1, B2, B3), and the B16-Exo-treated group (samples C1, C2, C3). B is a volcano map of differentially expressed genes, showing the changes in gene expression (|log 2 FoldChange|≥2, p<0.05), C is a network diagram of gene ontology (GO) analysis (B16-Exo gel vs IMQ), showing biological processes related to immune system processes, inflammatory responses and cell cycles, the size of the node represents the number of related genes, and the thickness of the line represents the number of co-expressed genes; D is the biological process involved in affecting T cell function after enrichment; E is the GSEA analysis result of the IL-17 signaling pathway, showing the enrichment trend and significance level (p-value) of IL-17 related genes in the B16-Exo treatment group compared with the IMQ treatment group; F is the KEGG pathway enrichment result (B16-Exo gel vs IMQ), showing the top 20 enriched pathways of genes downregulated in B16-Exo treatment relative to IMQ treatment, the ordinate represents the KEGG pathways with significantly enriched differential genes, and the abscissa shows the number of enriched genes in each pathway;

[0023] Figure 4The effects of various components in B16-Exo on T cell function in Experimental Example 5, A is a cell activity test showing the effects of different concentrations of B16-Exo, B16-Exo treated with proteinase K (Exo+Proteinase K), and Exo treated with RNaseA (Exo+RNaseA) on T cell activity; B is the effect of each treatment group on T cell proliferation by CFSE labeling analysis; C is the effect of each treatment group on T cell apoptosis by Annexin V-FITC / PI double staining flow cytometry analysis, D is the relative expression of IFN-γ level in T cell supernatant after treatment in each group, the data are expressed as relative units (au), and the baseline is the untreated Control group; E is the relative expression level of TNF-α in T cell supernatant after treatment in each group; the data are expressed as Mean±SD, and the * indicates statistical significance, where *p<0.05, **p<0.01, ***p<0.001;

[0024] Figure 5 In Experimental Example 6, the expression of IL-17a was targeted and downregulated by miRNAs in B16-Exo. A is a screening flowchart showing the steps of sequencing and analyzing miRNA and mRNA extracted from different samples, including miRNA sequencing, RNA sequencing, differential gene expression analysis, and prediction of potential miRNAs targeting IL-17A mRNA through databases such as miRDB, miRanda, DIANA-microT and TargetScan; B is a Venn diagram showing the miRNA mRNA interactions predicted by four major miRNA prediction databases (miRDB, miRanda, DIANA-microT, TargetScan), highlighting the 10 potential miRNA-mRNA pairs identified by all databases; Luciferase reporter gene analysis was used to verify the direct targeting of (C) mmu-miR-320-3p and (D) mmu-miR-126-5p to IL-17a 3'UTR, and the figure shows wild-type (WT) and mutant (MUT) IL-17a Luciferase activity of 3'UTR, data are expressed as luciferase activity relative to negative control (NC), mean ± standard deviation; E is co-cultured with Th17 cells to verify the effects of mmu-miR-320-3p and mmu-miR-126-5p on the level of IL-17 secretion by cells, * indicates statistical significance, where * represents p < 0.05, ** represents p < 0.01, *** represents p < 0.001, **** represents p < 0.0001;

[0025] Figure 6Figure 7 shows the epidermal cell uptake, intracellular localization, and transcellular transport mechanism of B16-Exo in Experimental Example 7. A shows the penetration of B16-Exo in normal skin and psoriasis model skin by fluorescence scanning of skin slices. The dotted line is the epidermal-dermal junction, and the scale bar = 100 μm. B shows the intracellular co-localization of Dio-labeled B16-Exo after uptake by HaCaT cells, and the scale bar = 20 μm. C shows the internalization of exosomes by cells under the action of different uptake inhibitors, and (D) the results of quantitative analysis by flow cytometry. E shows the intracellular transport pathway of exosomes. HaCaT cells were co-incubated with Dio fluorescently labeled exosomes for 6 h. hours, and then added lysosome (Lyso), endoplasmic reticulum (ER) or Golgi specific fluorescent markers, followed by confocal microscopy imaging; F is the intracellular co-localization result of B16-Exo and various organelles; G is the quantitative analysis of exosome exocytosis dynamics by flow cytometry, and the cells were pretreated with exosomes for 6 hours, and the fluorescence intensity at this time was normalized to the initial fluorescence intensity of exocytosis; H is the exocytosis efficiency of exosomes under the action of different intracellular transport inhibitors, and the cells pretreated with exosomes for 6 hours were taken, and different intracellular transport inhibitors were added, and the intracellular fluorescence intensity was quantitatively detected by flow cytometry; I is Western Blot analysis verified the expression of RhoA protein on B16-Exo and MSC-Exo; J is the flow cytometry fluorescence quantitative comparison of the efflux efficiency of B16-Exo and MSC-Exo; K is the effect of HaCaT cells on B16-Exo uptake after adding RhoA protein inhibitor, * indicates statistical significance, where * represents p<0.05, ** represents p<0.01, *** represents p<0.001, **** represents p<0.0001;

[0026] Figure 7 is the change in the body weight of mice in Experimental Example 1;

[0027] Figure 8 is the change in the body weight of mice in Experimental Example 2;

[0028] Fig. 9 is the change in the body weight of mice in Experimental Example 3;

[0029] Fig.10 The transcriptome sequencing technology was used to analyze the skin tissue samples in Experimental Example 4. A is the principal component analysis (PCA) showing the data distribution of the three experimental groups. The square, triangle and circle points represent A. control group, B. IMQ group and C. B16-Exo group, respectively. PC1 accounts for 63.5% of the data variability, showing significant differences between the groups. B is a heat map of gene expression. C is a comparison of gene expression changes between the IMQ model and the IMQ model. D is the expression of psoriasis-related cytokines, chemokines and other related genes after B16-Exo treatment, expressed as log2 fold change; negative values ​​indicate decreased expression, E is the enrichment of down-regulated genes in the B16-Exo treatment group compared with the IMQ group in the inflammatory response, skin development, and cell cycle process;

[0030] Fig.11 The IL-17 signaling pathway of differentially expressed genes after B16-Exo treatment in Experimental Example 4 was enriched by KEGG;

[0031] Fig.12 In Experimental Example 5, proteinase K and RNaseA were used to pre-treat exosomes for deproteinization and denuclease before co-culture with T cells. A is a schematic diagram of T cell isolation from mouse spleen. B is a flow cytometry control and sample spectra before and after separation showing CD4 + Positive cell markers;

[0032] Fig.13 The effects of various inhibitors on CD4 + Effects of B16-Exo uptake by T cells;

[0033] Fig.14 This is the time-dependent fluorescence distribution diagram of the exosome excretion dynamics after being taken up by cells in Experimental Example 7;

[0034] Fig.15 The protein sequencing and enrichment analysis of B16-Exo in Experimental Example 7, A is the KEGG enrichment analysis, and B is the high expression of RhoA protein in B16-Exo based on the GESA analysis results;

[0035] Fig.16 is the expression level of RhoA protein in B16-Exo determined by immunoblotting in Experimental Example 7, A is the comparison of RhoA protein expression between MSC and B16-F10, and B is the quantitative result of immunoblotting;

[0036] Fig.17 The flow cytometry analysis of the endocytic fluorescence distribution of B16-Exo and MSC-Exo at 4° and 37° in Experimental Example 7;

[0037] Fig.18 This is the effect of RhoA inhibitor on B16-Exo uptake by HaCaT cells in Experimental Example 7. DETAILED DESCRIPTION

[0038] In order to make the technical problems, technical solutions and advantages to be solved by the present invention more clear, a detailed description will be given below with reference to the accompanying drawings and specific embodiments.

[0039] The following examples are used to illustrate the present invention, but are not intended to limit the scope of the present invention. Without departing from the spirit and substance of the present invention, modifications or substitutions made to the methods, steps or conditions of the present invention are within the scope of the present invention.

[0040] Unless otherwise specified, the technical means used in the examples are conventional means well known to those skilled in the art; unless otherwise specified, the reagents used in the examples are commercially available.

[0041] Experimental Example 1: Study on the effect of melanoma tissue homogenate on the relief of psoriasis

[0042] 100uL of 100mg / mL (protein concentration) melanoma tissue homogenate was taken and applied to the lesion skin of psoriasis model mice with carbomer gel as the excipient matrix to evaluate its in vivo therapeutic effect.

[0043] Tumor homogenate tissue contains tumor cells, immune cells, and a variety of tumor cell secretions, which can simulate the complexity and immune regulation function of the in situ tumor microenvironment. Mice were treated with 62.5 mg of imiquimod (IMQ) daily for 7 consecutive days, and different concentrations (0 mg / mL, 50 mg / mL, 100 mg / mL and 150 mg / mL) of tumor tissue homogenate were given daily during this process. Figure 1 A). The results showed that as the dose increased, the various indicators of skin lesions (such as red macules, plaques and scales, etc.) gradually decreased ( Figure 1 B), indicating that the therapeutic effect of homogenate tissue on psoriasis is dose-dependent (based on total protein content). PASI score can also quantitatively reflect this trend ( Figure 1 C). In addition, the reduction in epidermal thickness further confirmed the therapeutic effect ( Figure 1 D). These results indicate that tumor tissue homogenate has a potential therapeutic effect on psoriasis. In addition, no changes in the body weight of mice were observed during the treatment ( Figure 7 ), indicating the safety of the treatment.

[0044] Experimental Example 2: Investigation of the main active components responsible for immunosuppression in melanoma tissue homogenate

[0045] Using in vitro cultured melanoma cells as the research object, the complex tumor tissue was decomposed into three main components: melanoma cells (B16-F10 cells), culture supernatant (Supernatant) and exosomes secreted by melanoma cells (B16-Exo) ( Figure 1E). It is known that all three have immunomodulatory functions. Melanoma tumor cells can interact with immune cells (T cells, NK cells, macrophages, etc.) and affect their functions; the culture supernatant contains cytokines (TGF-β and IL-10, etc.), which promote Treg cell proliferation and immune tolerance; exosomes may activate or inhibit specific signaling pathways by transmitting biological molecules (proteins and miRNAs), thereby regulating the state of immune cells.

[0046] First, B16-F10 cells and their supernatants were separated from the culture system. The supernatants were then centrifuged at 2,000 × g for 10 min to remove cells and debris, 10,000 × g for 60 min to remove larger vesicles, and then filtered through a 0.22 μm pore size filter (MF-Millipore) to exclude apoptotic bodies and microvesicles ( Figure 1 E). The filtrate was ultracentrifuged at 100,000 × g for 90 min at 4°C (model: Optima L-90K, rotor type 45Ti, Beckman Coulter), and the precipitated exosomes were resuspended in PBS and then ultracentrifuged again under the same conditions. The final pellet was resuspended in 200 μL PBS and centrifuged using Pierce TM BCA protein assay kit (Thermo Fisher Scientific) was used for quantification. The exosomes separated by TEM observation were wrapped by a double lipid membrane and had a typical ring structure ( Figure 1 F). DLS results showed that exosomes had a relatively uniform particle size distribution, and WB confirmed the presence of exosome-specific marker proteins CD63 and Alix ( Figure 1 G), thus confirming the successful separation of exosomes. The three separated components were evenly distributed in the carbomer matrix and applied to IMQ-induced psoriasis model mice via a transdermal route to evaluate their therapeutic effects. The results showed that among the three groups, only B16-Exo showed a significant improvement in skin lesions, with red macules and scales basically disappearing ( Figure 1 H), and also showed significant differences in PASI scores compared with the other two groups ( Figure 1 I). In addition, it was observed through skin tissue sections that B16-Exo significantly reduced the thickness of the epidermis compared with IMQ ( Figure 1 J), indicating that it relieved psoriasis lesions. It is speculated that B16-Exo is the key active ingredient in tumor tissue homogenate that has a therapeutic effect on psoriasis mice. In addition, the weight of mice did not change significantly during the treatment process ( Figure 8 ), further confirming the safety of this treatment strategy.

[0047] Experimental Example 3: Investigating the effect of melanoma exosomes B16-Exo on alleviating psoriasis by regulating T cells

[0048] Except for the control group, all mice received topical treatment with IMQ and 100uL exosome gel (exosome content 1ug) every day for 7 consecutive days. During the entire experimental period, only the mice in the control group did not show psoriasis pathological changes ( Figure 2 A). Compared with the IMQ and Blank gel groups, the B16-Exo gel group showed significant improvement in reducing erythema, stratum corneum thickness, and scaling, and its PASI score was significantly lower than that of the IMQ group ( Figure 2 B). In addition, this treatment showed low toxicity in terms of body weight changes in mice ( Fig. 9 From a histological perspective, the skin of mice in the IMQ group showed severe keratinization and inflammatory cell infiltration, the thickness of the epidermis increased significantly, and keratinization was incomplete, accompanied by inflammatory cell infiltration in the dermis and massive cell death in the sebaceous glands ( Figure 2 C). In contrast, after B16-Exo gel treatment, the above skin lesions of mice were significantly alleviated. In terms of immunity, the B16-Exo gel group significantly reduced the weight and volume of the mouse spleen, approaching the level of the Control group ( Figure 2 DE). It was also found from spleen sections that compared with Control, the volume of lymphoid follicles in IMQ and Blank gel was significantly increased ( Figure 2 F), indicating that the systemic immune response was enhanced after modeling. After receiving B16-Exo gel treatment, the volume of splenic lymphoid follicles was significantly reduced, indicating that the immune response was suppressed.

[0049] To further explore the role of B16-Exo in the local immune environment, the expression levels of immune factors in the skin tissue of psoriasis mice were examined. Compared with IMQ and Blank gel, the level of IL-23 produced by DCs decreased slightly after B16-Exo gel treatment ( Figure 2 G), but a series of T cell-mediated pro-inflammatory factors, including IL-17, TNF-α, IL-1β and IL-6, showed significant downregulation ( Figure 2 HK). IL-17 is secreted by Th17 cells, directly stimulating the proliferation of keratinocytes and promoting the production of other inflammatory factors, such as TNF-α and IL-1β, which further maintain and aggravate the inflammatory state of psoriasis. Therefore, B16-Exo can effectively cut off the inflammatory feedback loop by significantly reducing the expression of these key pro-inflammatory factors, thereby alleviating the pathological changes of the skin. It is speculated that the therapeutic effect of B16-Exo may be achieved by regulating T cell activity and its function.

[0050] Experimental Example 4: Investigating the inhibition of T cell activity by B16-Exo and regulating the IL-17 signaling pathway

[0051] Transcriptome sequencing was used to analyze skin tissue samples treated with IMQ, Blank gel, and B16-Exo gel. To ensure the accuracy and reliability of bioinformatics analysis, principal component analysis (PCA) was first used to verify the consistency of experimental data and differences between groups.

[0052] The results showed that there was a clear separation between samples from different treatment groups, and samples within the same treatment group showed a high degree of consistency ( Fig.10 -A). The heat map and dendrogram cluster analysis of the three groups of gene expression showed that after IMQ treatment, the expression of specific genes was significantly upregulated, while B16-Exo gel treatment could restore the expression of these genes to levels close to those of the normal control group ( Fig.10 -B), suggesting that B16-Exo gel may offset the pathological effects of the psoriasis model through a specific gene regulatory mechanism. Further differential gene analysis revealed that B16-Exo gel significantly reduced the expression difference between the Control and IMQ groups ( Fig.10 -C), which confirmed its therapeutic effect on the psoriasis model.

[0053] In order to understand the pathological significance of the expression differences among the groups, we focused on the expression changes of genes related to Epidemisdevelopment and Chemokine & cytokine activity, which are highly related to psoriasis. These genes were significantly upregulated after IMQ modeling ( Figure 3 A) Verifies the validity of the model. After treatment with B16-Exo gel, the expression levels of these marker genes were significantly reduced to a level similar to that of the Control group.

[0054] In addition, B16-Exo gel treatment also downregulated a series of metalloproteinases, antimicrobial peptides, phospholipase A2-related genes and their pathways, which are responsible for tissue reconstruction, innate immunity, and cell membrane phospholipid metabolism ( Fig.10 DE). Subsequently, we focused on the differentially expressed genes between the B16-Exo gel and IMQ groups and found that the expression of several pro-inflammatory genes closely related to the immune response of psoriasis, such as IL17a, TNF-α, IL1b, and IL6, were significantly downregulated ( Figure 3 B), which is consistent with the changes in inflammatory factors in skin tissue mentioned above, further clarifying the anti-inflammatory effect of B16-Exo gel.

[0055] Gene ontology (GO) enrichment analysis was performed on the downregulated genes after differential analysis (B16-Exo gel vs IMQ). The analysis revealed that B16-Exo gel treatment effectively downregulated biological processes related to inflammation and cell proliferation ( Figure 3C). In addition, the results of enrichment analysis related to T cell function showed that B16-Exo gel significantly inhibited the activation and proliferation of T cells and the differentiation of Th17 cells ( Figure 3 D). This finding is consistent with the previous animal experiments that B16-Exo gel has an inhibitory effect on T cells. In addition, GSEA analysis showed that genes related to the IL-17 signaling pathway were negatively enriched in the B16-Exo gel treatment group, indicating that B16-Exo gel can effectively downregulate the IL-17 pathway and the expression of its key gene IL-17 in psoriasis skin tissue ( Figure 3 E). This was further verified in the KEGG (Kyoto Encyclopedia of Genes and Genomes) enrichment results, showing that B16-Exo gel treatment significantly downregulated the "IL-17 signaling pathway" in the skin tissue of IMQ mice ( Figure 3 F), especially the expression of IL-17a ( Fig.11 IL-17a, as the main secretion of Th17 cells, promotes inflammatory response and keratinocyte proliferation by activating multiple cells to produce inflammatory mediators. The overexpression of IL-17a usually reflects the abnormal activity of Th17 cells. Therefore, the effect of B16-Exo gel may be to inhibit the activity of this T cell subset, reduce the expression of IL-17a, cut off the inflammatory feedback loop, and thus achieve effective treatment of psoriasis.

[0056] Experimental Example 5: Investigating the role of B16-Exo in regulating T cells through RNA in its structure

[0057] After clarifying the regulatory mechanism of B16-Exo on T cell function, we further explored its active ingredients. The active substances in the exosome structure mainly include proteins and RNA. Proteinase K and RNaseA were used to pre-treat the exosomes for deproteinization and denucleic acid, respectively. Primary CD4 + T cells ( Fig.12 AB), and further investigated the interference of different components of exosomes on T cells in vitro. The results of MTT experiments showed that B16-Exo could inhibit the proliferation activity of T cells in a dose-dependent manner ( Figure 4A), which is consistent with the T cell inhibition effect of the above sequencing results. Both Proteinase K and RNase A pretreatment can weaken the activity of B16-Exo, but the effect of RNaseA pretreatment is greater. At a higher concentration (100ug / mL), there was a significant difference between the RNase A and Proteinase K pretreatment groups, indicating that the RNA molecules in the B16-Exo structure may play a more critical role in immunosuppression than proteins. The CFSE proliferation experiment also confirmed this. After B16-Exo and Proteinase K+B16-Exo treatment, the CD4 + T cells showed obvious inhibitory effects, but a new cell division peak appeared in the RNaseA+B16-Exo group, which failed to effectively inhibit CD4 + T cell proliferation ( Figure 4 B). In addition, the results of AnnexinV-FITC / PI double staining flow cytometry experiments showed that compared with the RNaseA+B16-Exo group, the B16-Exo and Proteinase K+B16-Exo treatment groups promoted a higher proportion of CD4 + Early T cell apoptosis Figure 4 C). Then the changes of cytokines in T cells were measured. B16-Exo can significantly reduce IFN-γ ( Figure 4 D) and TNF-α ( Figure 4 E) levels, indicating the anti-inflammatory effect of the exosomes. Similarly, after RNaseA pretreatment, the inhibitory effect of B16-Exo on inflammatory factors was significantly weakened, further clarifying the main contribution of RNA molecules in exosome-mediated immunosuppression. The above results show that compared with the protein component, the RNA in B16-Exo plays a more important role in inhibiting CD4 + T cell proliferation and inflammatory response play a more critical role.

[0058] Experimental Example 6: Investigating the regulatory role of miRNAs in B16-Exo in the IL-17 signaling pathway

[0059] Combining multiple bioinformatics tools such as miRanda, miRDB, DIANA-microT and TargetScan analysis ( Figure 5 A), we identified ten candidate miRNAs that may be involved in regulating the downregulation of IL-17a expression ( Figure 5B). Subsequently, the abundance data obtained from exosomal miRNA sequencing were combined to further identify two potential key regulatory molecules: mmu-miR-320-3p and mmu-miR-126-5p. In order to verify the functions of these miRNAs, luciferase reporter gene vectors with IL-17a mRNA 3' untranslated region (3'UTR) were constructed and transfected into HEK293T cells to verify the regulatory role of miRNA.

[0060] The experimental results showed that mmu-miR-320-3p could significantly inhibit the luciferase activity of the wild-type IL-17a 3'UTR reporter gene, but had no inhibitory effect in the 3'UTR mutant type ( Figure 5 C). mmu-miR-126-5p also showed an inhibitory effect on IL-17a, but its potency was weaker than that of mmu-miR-320-3p ( Figure 5 D). Studies have shown that human hsa-miR-126-5p, which is homologous to mmu-miR-126-5p, also has the ability to downregulate IL-17a. Subsequently, in order to further verify the regulatory role of these miRNAs in T cells, we first induced CD4 + T cells differentiated into Th17 cells, increasing the expression of intracellular IL-17. Then, two candidate miRNAs were transfected to compare their ability to inhibit IL-17. The results showed that compared with mmu-miR-126-5p, mmu-miR-320-3p had a stronger IL-17 downregulation effect ( Figure 5 E), which is consistent with the trend of the luciferase activity experiment. In summary, mmu-miR-320-3p in B16-Exo plays a key role in regulating IL-17a expression, showing its potential as an immunomodulator and potential therapeutic molecule for psoriasis.

[0061] Experimental Example 7: Investigating the transdermal penetration of B16-Exo via RhoA protein-mediated transcytosis

[0062] An important prerequisite for the topical application of B16-Exo to exert its anti-psoriatic effect is effective percutaneous penetration, especially for psoriatic lesions with abnormally proliferating and dense keratinocytes. B16-Exo was labeled with Dio fluorescent dye to track its percutaneous penetration behavior.

[0063] In normal skin samples, most B16-Exo penetrated into the dermis within 6 hours ( Figure 6A). In the psoriasis model, due to the density and thickening of the skin stratum corneum, the penetration time was extended to 12 hours. As a control, no obvious fluorescence was observed for free Dio fluorescein in the skin tissue, further confirming the transdermal penetration of fluorescein mediated by B16-Exo. The above results show that B16-Exo has excellent transdermal properties and can penetrate normal skin and psoriasis-thickened epidermis. Subsequently, the principle of B16-Exo transdermal penetration was further explored. A series of cell experiments were carried out to explore its uptake and transport behavior in the skin barrier. First, through fluorescent labeling and co-localization analysis, it was confirmed that B16-Exo can be effectively taken up by human epidermal keratinocytes (HaCaT) ( Figure 6 B).

[0064] To explore its cellular internalization mechanism, a series of endocytic pathway inhibitors were used, including colchicine (inhibits microtubule-based transport), chlorpromazine (blocks vesicle-mediated phagocytosis), cytochalasin D (prevents actin polymerization and related phagocytosis) and nystatin (inhibits ergosterol and changes the permeability of the cell membrane). The results of fluorescence co-localization and flow cytometry quantitative uptake rate showed that chlorpromazine significantly affected the cellular uptake of B16-Exo ( Figure 6 CD, Fig.13 ), which indicates that the cellular internalization process of B16-Exo is mainly regulated by vesicle-mediated phagocytosis.

[0065] Further observation of the intracellular transport behavior of B16-Exo revealed that it was mainly co-localized with the endoplasmic reticulum and Golgi apparatus, while less marked in the lysosome ( Figure 6 EF), indicating that it is mainly transported through the endoplasmic reticulum and Golgi apparatus and may achieve lysosomal escape, which contributes to the stability and functional delivery of the bioactive substances it carries.

[0066] After the fluorescently labeled B16-Exo was co-cultured with HaCaT for 6 hours and taken up, the changes in the intracellular fluorescence signal were tracked to evaluate the exosome excretion behavior. The experimental results showed that the intracellular fluorescence signal gradually weakened over time, especially after 12 hours, most of the fluorescently labeled exosomes had been excreted from the cells, preliminarily confirming their excretion behavior in the cells ( Figure 6 G, Fig.14). Further, to explore the transcytosis mechanism of exosomes, we imposed different interferences on the cells after the exosomes were taken up, including cooling to 4°C to block metabolic suspension of excretion, using Monensin to disrupt the pH balance of the Golgi apparatus, BrefeldinA to block the transport of substances from the endoplasmic reticulum to the Golgi apparatus, and Nocodazole to destroy the microtubule network. The results showed that the treatment group with 4°C suspension of exocytosis showed the highest fluorescence intensity, indicating that low temperature effectively suspended the transcytosis process. At the same time, the three inhibitor treatments reduced the excretion of B16-Exo and weakened the intracellular fluorescence intensity, indicating that multiple cellular transport pathways are jointly involved in the transcytosis of B16-Exo ( Figure 6 H). Among them, the relative fluorescence signal after treatment with Monensin was the strongest, highlighting the key role of the Golgi apparatus in the transcellular transport of exosomes.

[0067] To further clarify the endocytic transport mechanism of B16-Exo, protein sequencing and gene set enrichment analysis (GSEA) were performed on its structure. It was found that B16-Exo protein was significantly enriched in the AXON-GUIDANCE pathway ( Fig.15 A). This result suggests that B16-Exo may regulate the migration and dynamic behavior of cells by affecting axon guidance molecules.

[0068] In order to specifically explore which proteins may affect this motility behavior, differential protein analysis was performed using exosomes secreted by mouse skin cells (JB6) as a biological control to identify the molecular differences between exosomes secreted by normal and cancerous skin cells. Compared with JB6 exosomes, we observed significantly higher expression of RhoA protein in B16-Exo ( Fig.15 B). As a small Rho GTPase, RhoA plays a central role in the dynamic regulation of the cytoskeleton and can interact with multiple axon guidance signals such as Netrin and Semaphorins to regulate cell behavior under the signaling pathway. These axon guidance molecules further mediate actin polymerization and microtubule stabilization through RhoA-activated signal transduction, thereby significantly affecting the directional movement and morphological changes of cells. Based on these findings, it can be predicted that the efficient intercellular transmission ability of B16-Exo may be closely related to the key role of RhoA in regulating microtubule dynamics and cytoskeletal reorganization.

[0069] To further clarify the unique ability of B16-Exo in intracellular transport and transdermal penetration, we compared it with the commonly used mesenchymal stem cell exosomes (MSC-Exo). MSC-Exo is the most widely studied and used exosome and is considered to be a representative of functional exosomes. WB analysis showed that the expression of RhoA protein in B16-Exo was significantly higher than that in MSC-Exo ( Figure 6 I, Fig.16 ). Subsequently, the transcytosis ability of B16-Exo and MSC-Exo in cells was evaluated by flow cytometry. By comparing the treatment at 4°C, it was found that the relative fluorescence of B16-Exo retained in cells was stronger after low temperature treatment ( Figure 6 J), indicating that the exosomes have a stronger efflux effect, which is consistent with the expression trend of RhoA protein ( Fig.17 ).

[0070] In order to more directly verify the role of RhoA protein in the transcellular transport of exosomes, we used RhoA specific inhibitors MLS00532223 and Rhosin for pretreatment and found that both inhibitors could completely block the cell uptake of B16-Exo ( Figure 6 K, Fig.18 ).

[0071] The above results reveal the mechanism of B16-Exo transport between epithelial cells and clarify that RhoA protein plays an important role in it.

[0072] The above is only a preferred embodiment of the present invention, and the protection scope of the present invention is not limited to the above embodiments. For those skilled in the art, improvements and changes obtained without departing from the technical concept of the present invention should also be regarded as the protection scope of the present invention.

Claims

1. Use of melanoma-derived exosomes in a drug for treating psoriasis, characterized in that: The drug includes melanoma-derived exosomes and matrix.

2. The use according to claim 1, characterized in that: The method for preparing melanoma-derived exosomes is as follows: B16-F10 cells and their supernatant are separated from the culture system, the supernatant is centrifuged to remove cells, debris and large vesicles in sequence, and then filtered through a filter to exclude apoptotic bodies and microvesicles, the filtrate is ultracentrifuged to obtain a precipitate, which is resuspended and ultracentrifuged again to finally obtain a precipitate as exosomes.

3. The use according to claim 2, characterized in that: The centrifugal force for removing cells and debris was 2,000 g, and the centrifugal time was 10 minutes. The centrifugal force for removing large vesicles was 10,000 g, and the centrifugal time was 60 minutes.

4. The use according to claim 2, characterized in that: The pore size of the filter is 0.22 μm.

5. The use according to claim 2, characterized in that: The centrifugal force of the filtrate ultracentrifugation is 100,000 g and the ultracentrifugation time is 90 min.

6. The use according to claim 2, characterized in that: The effective pharmacological concentration of the melanoma-derived exosomes in the drug is 0.01 mg / mL, and the matrix includes carbomer gel.

7. The use according to claim 2, characterized in that: The drug is applied externally, directly on the affected skin.

Citation Information

Patent Citations

  • Application of reagent in preparation of medicine for treating / inhibiting psoriasis

    CN113855807A

  • Hydrogel loaded with amniotic mesenchymal stem cell exosome as well as preparation method and application of hydrogel

    CN118356443A